Kornimate/medical-research-clean huggingface dataset:
white coat hypertension and antihypertensive treatment effect - scor in hypertension

Conditions: Cardiovascular Diseases; Heart Diseases; Hypertension

Summary: to investigate the mechanisms of white coat hypertension and study it further as a risk factor for heart damage.

background: the multidisciplinary scor examined causes, consequences, and treatments of human hypertension. a central theme was the renal basis for human hypertension. the subproject on white coat hypertension began in december of 1985. design narrative: in the longitudinal study, eighty patients with white coat hypertension were compared with 40 age- and sex-matched normotensives, and with 80 patients with sustained hypertension. the protocol consisted of (a) clinic blood pressure measurements made both by a physician and a nurse, (b) self-monitoring at home, (c) noninvasive ambulatory monitoring, (d) reactivity testing (cold pressor test, mental arithmetic, and isometric exercise) and (e) korotkoff signal recording. patients were also tested for early markers of disease (echocardiography and urine albumin). the 80 patients in each of the two hypertensive groups were randomized to one of four treatment protocols (20 patients each); an alpha blocker, a beta blocker, a combined alpha- and beta-blocker, or an ace inhibitor. the doses of medication were adjusted to produce similar reductions of clinic blood pressure in the different groups. the test battery (a-e) was reported during treatment. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
probiotics in prevention of allergies, obesity and caries

Conditions: Eczema; Allergy; Asthma; Obesity; Dental Caries

Summary: during the period of 2000-2003, 179 healthy, term infants with no previous signs of allergic disease were recruited and randomized to daily intake of cereals with or without the addition of lactobacillus paracasei subspecies paracasei strain f19 (lf19) from 4-13 months of age. the effects of lf19 on gut microbial composition, infections, allergies, immunological development, growth and blood lipids were monitored. of 179 included infants, 171 completed the study. the study product was well tolerated with no observed side effects. compliance was excellent. in a follow-up study, the aim is to investigate the long-term effects of feeding lf19 during weaning on allergies, immune programming, overweight, gut microbial composition and oral health in 8-year old children. the investigators' primary outcome will be to determine whether daily intake of lf19 during weaning results in less eczema at 8 years of age, and if the preventive effect encompasses also respiratory allergies and immunoglobulin e (ige) - sensitization. the long term effects on gut microbial composition, overweight and metabolic markers will be investigated. furthermore, the possible preventive effects of lf19 on caries will be assessed.


Eligibility criteria:
inclusion criteria: * healthy infants born at term (gestational age 37-42 weeks) * birth weight \> 2500 g * vaginally delivered * no atopic manifestation * a normal diet for age * no medication that could have affected the intestinal microbiota

Keywords: prevention probiotics eczema allergy asthma obesity caries gut microbiota
pre-exposure prophylaxis (prep) provision for ugandan fisherfolk

Conditions: HIV

Summary: this study is a pilot test of enhancements to the standard of care for providing prep in ugandan fishing communities. the specific aims are to conduct a mixed-methods study assessing enhancements to the standard of care for providing prep in fisherfolk communities in lake victoria, uganda.

the study will take place at two landing sites at which prep is provided to fisherfolk through the ugandan national prep program. the comparison site will receive the standard of care for prep provision. at the intervention site, the investigators will implement a three-pronged intervention: 1. during healthcare outreach events we will conduct prep workshops, in which people who want to know more about prep learn basic facts about prep and are taught skills about how to advocate for prep in their community. 2. check-in calls: to support prep adherence, healthcare workers will call prep users two weeks after initiation, and the week before refill events, to check in about any questions and to remind them of the next date and place to pick up refills. calls after prep initiation will ask about side effects. 3. to support prep adherence, healthcare workers will encourage prep users to select an adherence supporter, who is a family member or friend to whom they disclose their prep use. the adherence supporter agrees to remind the prep user to adhere to prep and get refills. healthcare workers will ask the prep user for the name and contact information for the adherence supporter, so that the adherence supporter can be contacted to remind them about refills, as well as if the prep user does not show up for a refill.

Eligibility criteria:
inclusion criteria for prep initiation: * tests hiv-negative at a healthcare outreach/hiv testing event in one of the two selected fishing communities and is prep-eligible exclusion criteria: * not meeting the inclusion criteria

Keywords: prep fisherfolk uganda hiv/aids
tele-assessment and face-to-face evaluation of functional gait assessment in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the aim of the study is to examine the reliability of the method by applying the functional gait assessment in patients with multiple sclerosis via online video conferencing. for this purpose, walking of each patient to be included in the study; the evaluation results will be compared and the intra-rater reliability will be investigated by evaluating both face-to-face and online video conferencing methods. since the functional gait assessment is not available in turkish, the scale will also be validated by adapting it to turkish within the scope of the study.

as with all neurological diseases, it is important to use appropriate outcome measurements in the assessment of balance and gait disorders in patients with multiple sclerosis (ms), in order to determine the appropriate program for the patient in physiotherapy and rehabilitation applications, both face-to-face and through telerehabilitation. the scale recommended by a clinical practice guide developed with the support of the american physiotherapy association (apta) and the academy of neurological physiotherapy (anpt) is the functional gait assessment (fga). according to this proposal, a turkish version will be made within the scope of the study so that functional walking evaluation can be used in our country. a 2017 study on functional gait assessment and multiple sclerosis investigated the validity and sensitivity to changes in the original english version of the test in multiple sclerosis, and as a result, its validity was found for ms. functional gait assessment does not have a reliability study for multiple sclerosis.

Eligibility criteria:
inclusion criteria: * having a definite diagnosis of ms of any clinical type according to the 2017 mc donalds criteria by a neurologist, * 18 years and over * expanded disability status scale (edss) score of 2,5-6 * not having an attack within the last 30 days * voluntarily giving consent to participate in the study * absence of visual and auditory impairment for completion of assessments for tele-assessment: * having a walking area of at least 3 meters at home to evaluate walking * providing a care provider's supervision to ensure walking safety * the patient or the caregiver can use the video conferencing software application from the phone or computer exclusion criteria: * diagnosis of another neurological disease that affects the level of ambulation other than ms * receiving corticosteroid therapy within the last 1 month * limitation in range of motion of the lower extremities, which may affect standing and walking * pain that negatively affects walking in the lower extremity and lumbar area (etc., coxarthrosis, gonarthrosis, sciatica) * inability to stand up from a sitting position (timed up \& go test requirement)

Keywords: teleassessment functional gait assessment balance walk
intermittent vs. continuous dorsal root ganglion stimulation

Conditions: Pain, Intractable; Pain, Chronic

Summary: the purpose of this study is to evaluate and compare the therapeutic efficacy of intermittent dorsal root ganglion stimulation (drg-s) to standard continuous stimulation in patients with chronic intractable pain

intermittent dorsal root ganglion stimulation (drg-s) dosing consists of preprogrammed cycles during which stimulation is delivered with standard drg-s parameters alternated with periods during which no stimulation is being delivered. in this study the investigators propose to evaluate therapeutic efficacy of intermittent drg-s at 1 minute on: 1 minute off and 1 minute on: 2 minute off dosing in comparison to standard continuous drg-s dosing and determine if there is noninferiority between the intermittent and continuous paradigms in chronic pain patients with permanent drg-s implants.

Eligibility criteria:
inclusion criteria: * subject is able to provide informed consent to participate in the study; * subject is 21 years of age or older; * subject has been treated with drg-s permanent implant device (abbott, plano, tx, usa) for a minimum of 3 months with sustained pain relief \>50% for chronic intractable pain; * subject's drg-s parameters have remained unchanged for at least 30 days prior to the beginning of the study exclusion criteria: * subject had a recent change in pain medication regimen resulting in increase in morphine milligram equivalent dosing within 60 days prior to the beginning of the study * subject received an additional pain interventional procedure within 60 days prior to the beginning of the study

Keywords: dorsal root ganglion stimulation intermittent stimulation dosing
correlation between maximal inspiratory pressure and hand grip force

Conditions: Healthy

Summary: this study aimed to examine the possible relationship between hand grip strength (hgs) and maximum inspiratory pressure (mip) in healthy individuals.

this study aimed to examine the possible relationship between hand grip strength (hgs) and maximum inspiratory pressure (mip) in healthy individuals. all individuals underwent assessment of inspiratory muscle strength by maximum inspiratory pressure, and evaluation of hand grip strength. mip was measured using a u-type water manometer calibrated in centimetre of water (cmh2o), while the hgs was measured with hydraulic hand dynamometer calibrated in kg.

Eligibility criteria:
inclusion criteria: * healthy individuals exclusion criteria: * age \<20 years old, * pregnancy, * official diagnosis with lung disease such as chronic obstructive pulmonary disease (copd), * body mass index (bmi) \> 40, * known pre-existing causes of neuromuscular weakness, * median entrapment neuropathy such as carpal tunnel syndrome

Keywords: mip hand grip correlation inspiratory pressure hand grip force
german chest pain unit (cpu)-register

Conditions: Chest Pain

Summary: the chest pain unit (cpu) register is a nationwide scientific investigation, in which data concerning the hospital-stay within the chest pain unit are documented. furthermore, a follow-up via telephone is conducted after 3 months.

the aim of a chest pain unit (cpu) is to clarify unclear chest pain quickly and specifically. present data from germany, the usa and england prove that the organisation models of a cpu lead beside a drastic reduction of mortality also to a cost reduction as well as a shortening of the average inpatient hospital stays. therefore it seems reasonable to assign a minimum standard to cpus. although there are internationally already standards for cpus up to complete certification programmes, it is an explicit wish of the german society for cardiology (dgk) to create an own standard which considers on the national circumstances. the aim of the cpu register is the internal and external validation of the care quality of cpu including benchmark reports and risk-adjusted comparisons.

Eligibility criteria:
inclusion criteria: all patients that are admitted to a chest pain unit are included in this register. exclusion criteria: missing informed consent (informed consent can not be given in the acute phase of the disease, if consciousness is limited at that time; instead the patient will be asked for his consent at a later point of time, when he is fully conscious).

Keywords: chest pain unit myocardial infarction register admission to a chest pain unit for any reason
efficacy of breast milk expressed and sucrose in procedural pain in preterm

Conditions: Pain; Premature Infant; Human Milk; Breastfeeding

Summary: the aim of this study is to assess the non-inferiority of non- pharmacological breast milk expressed versus oral sucrose in relief procedural pain of venipuncture in preterm neonates. this is an experimental comparative study of non-inferiority randomized crossover, to be performed in neonatal units of hospitals in the community of madrid. the 54 pair of preterm that after the selection criteria are included in the study, they performed the randomization of the sequence and breast milk expressed receive oral or 24% sucrose. the doses administered are: 0.1ml preterm less than 27 weeks corrected gestational age (cga), 0.25 ml for infants 27 to 31 weeks cga and 0.5 ml for infants of 32-37 weeks. both groups will be accompanied by non-nutritive sucking and swaddling and administered two minutes prior to venipuncture. the outcome variable, pain, will be determined by the scale premature infant pain profile (pipp) and by percent of cry. data for the primary objective was analysed per intention to treat. this study was approved by local ethical committee.


Eligibility criteria:
inclusion criteria: * preterm neonates. * weight less than 2500 grams. * feed breastfeeding (exclusive or not) or can obtain weight expressed breastmilk . * be informed and consent to the parents of those infants previously requested. exclusion criteria: * maternal use of opioids or insulin-depent * infants with invasive artificial respiration * infants with major congenital anomalies * infants with grade ii or iv intraventricular hemorrhage or strokes * receiving parental sedatives or vasoactive drugs * infants with necrotizing enterocolitis * with surgical interventions * infants in absolute diet * infants with abstinence syndrome

Keywords: pain premature infant sucrose breastfeeding expressed breast milk pipp
effect of sglt2i on diabetic retinopathy in type 2 diabetes mellitus patients

Conditions: Diabetic Retinopathy

Summary: a prospective, randomized, open-label, controlled clinical trial will be conducted at the endocrinology department - ain shams university (asu) hospital. sixty patients will be enrolled into the study. 30 of which will receive dapagliflozin 10mg tab once daily and the other thirty will receive their standard antidiabetic therapy for 12 weeks.

all type 2 diabetes mellitus patients presenting to the endocrinology department, asu hospitals, who were diagnosed with mild to moderate non-proliferative diabetic retinopathy will be assessed for eligibility. eligible patients will be randomly assigned to one of the following 2 arms: 1. group 1 (control group) (n= 30): type 2 diabetes mellitus patients who will receive their oral antidiabetic for 12 weeks. 2. group 2 (test group) (n= 30): type 2 diabetes mellitus patients who will receive their oral antidiabetic along with dapagliflozin at a dose of 10 mg daily for 12 weeks. a total of four visits one for baseline evaluation and one for end of study evaluation and two intermediate visits, the following will be performed in the visits: 1. clinical evaluation 1. systolic and diastolic blood pressures recording. 2. plasma glucose measurement. 2. report any adverse effects that may appear 3. blood samples will be taken at baseline and at 12-week visits 4. follow up

Eligibility criteria:
inclusion criteria: 1. female or male aged between 40 and 70 years old. 2. glomerular filtration rates \> 60 ml/min. 3. normal aspartate and alanine transaminase levels. 4. controlled systolic and diastolic blood pressures exclusion criteria: 1. patients using insulin or more than one oral anti-diabetic drug. 2. patients who have hba1c level ≥10% (86 mmol/mol) or a fasting plasma glucose level \>240 mg/dl. 3. patients with a history of cardiovascular events within six months before enrolment. 4. patients suffering from cataract or glaucoma. 5. patients with volume depletion clinical signs. 6. body mass index (bmi) \>40 kg/m2 7. infectious or inflammatory diseases. 8. neoplasm, or hematological disorders. 9. pregnant or breast-feeding patients. 10. active participation in another clinical study.

Keywords: diabetic retinopathy sodium-glucose cotransporter-2 inhibitor
effect of augmented reality on pain, anxiety, and fear in children during blood collection

Conditions: Pain; Fear; Anxiety

Summary: in recent years, technological advances have enabled the development of innovative intervention methods in healthcare. this study aims to examine the effect of augmented reality (ar) technology on pain, anxiety and fear in children during pediatric blood collection procedures. the study is based on a randomized controlled design. participants were randomized into two groups, the group receiving ar intervention and the control group receiving standard care. pain, anxiety and fear levels will be assessed with pre and post intervention measurements.


Eligibility criteria:
inclusion criteria: * both parent and child voluntarily agree to participate in the study * no language barrier exclusion criteria: * parents or children who refused to participate in the study * problems with looking at the screen
haptoglobin and diabetes complications in pregnancy

Conditions: Diabetes in Pregnancy

Summary: pregnancies of patients with diabetes are associated with increase adverse pregnancy outcome . the risk for vascular complications including: intra uterine growth restriction (20%), hypertension (31%), preeclampsia (15%), eclampsia and placental abruption are significantly greater than those in background populations. the risk of developing vascular complications in diabetes pregnancies although is correlated with the severity and length of the disease is not fully understood. enhanced oxidation has been suggested to be the underlying abnormality responsible for some of the complications of diabetes. haptoglobin (hp) is an abundant plasma glycoprotein produced in the liver. the best understood function of hp is to bind free hemoglobin (hb) released from red blood cells. extracorpuscular hb is a potent fenton reagent.capable of of inflicting oxidative tissue damage. hp binds to hb and serves to inhibit the oxidative potential of hb by preventing the release of heme iron. the haptoglobin (hp) gene at chromosomal locus 16q22 is polymorphic, with two common alleles denoted 1 and 2. the prevalence of hp 1-1, hp 1-2 and hp 2-2 genotypes is approximately 16%, 48% and 36%, respectively. in the western world. a total of five independent longitudinal studies have demonstrated that dm individuals with hp 2-2 genotype have a two to five-fold increased risk of cvd as compared to dm individuals without the hp 2-2 genotype we sought to determine whether hp genotype plays important role in development of vascular complications in pregastational pregnancies. and whether hp genotype 2-2 is a risk factor for developing gestational diabetes (gdm)


Eligibility criteria:
inclusion criteria: * diabetes in pregnancy exclusion criteria: * not willing to participate
effects of the effects of dietary oils on fasting lipoprotein lipids

Conditions: Hypercholesterolemia

Summary: the objectives of this clinical trial are to assess the effects of dietary oils on blood lipids and other aspects of the fasting lipoprotein profile in healthy men and women with elevated cholesterol


Eligibility criteria:
inclusion criteria: * fasting ldl-c level equal to or greater than 130 mg/dl and less than 200 mg/dl at visit 1 * fasting triglycerides less than or equal to 350 mg/dl at visit 1 exclusion criteria: * has coronary heart disease or coronary heart disease risk risk equivalent, such as diabetes, atherosclerosis, etc * taking lipid medications intended to alter the lipids profile, including but not limited to statins, bile acid sequestrants, etc. * uncontrolled hypertension (systolic greater than or equal to 160 mm hg or diastolic greater than or equal to 100 mm hg)

Keywords: cholesterol,ldl vegetable oils heart diseases
compare efficacy/safety of repeat doses of ferumoxytol with iron sucrose in ckd subjects with ida and on hemodialysis

Conditions: Iron Deficiency Anemia Treatment; Chronic Kidney Disease(CKD)

Summary: the objectives of this study are to compare the efficacy and safety of repeat doses of intravenous (iv) ferumoxytol with iv iron sucrose for the treatment of ida in subjects with hemodialysis-dependent ckd.

this was a phase iv, randomized, open-label, active-controlled, multicenter clinical trial designed to evaluate the safety, efficacy, and frequency of use of ferumoxytol compared to iron sucrose for the episodic treatment of ida in hemodialysis subjects with ckd over a 1-year period. as part of this main study, an oxidative stress substudy and an mri substudy were conducted. the oxidative stress substudy, to be run concurrently with the initial tp of the main study, was to examine the varying degrees to which iron sucrose and ferumoxytol may or may not induce oxidative stress in vitro in subjects undergoing hemodialysis. the mri substudy, to be run concurrently with the main study and continue for an additional 11 months, was to assess the potential for deposition of iron in cardiac, hepatic, and pancreatic tissues and changes in laboratory parameters over a 2-year period.

Eligibility criteria:
key inclusion criteria include: 1. males and females ≥18 years of age 2. diagnosis of ckd 3. subjects on dialysis must have been on dialysis for at least 3 months prior to screening 4. female subjects of childbearing potential who are sexually active must be on an effective method of birth control for at least 1 month prior to screening and agree to remain on birth control until completion of participation in the study key exclusion criteria include: 1. history of allergy to either oral or iv iron 2. female subjects who are pregnant or intend to become pregnant, breastfeeding, within 3 months postpartum, or have a positive serum or urine pregnancy test 3. parenteral iron therapy within 30 days prior to screening or red blood cell (rbc)/whole blood transfusion within 14 days prior to screening or planned during the study

Keywords: iron deficiency anemia (ida) chronic kidney disease (ckd) hemodialysis magnetic resonance imaging (mri) ferumoxytol feraheme